Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: The need for a global approach in the management of cardiovascular risk factors

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 521-526

  Tuñón, José ^a   Martín Ventura, José Luis ^a   Blanco Colio, Luis Miguel ^a   Tarín, Nieves ^b   Egido, Jesús ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

Angiotensin; Atherosclerosis; Endothelium; Hypercholesterolemia; Hypertension; Inflammation

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LIPID; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; POLYPHARMACY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTORS; THROMBOSIS;

EID: 35048852211     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Barnes PJ, Karin M. 1997. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 336:1066-71.
2. Blanco-Colio LM, Tuñón J, Martin-Ventura JL, et al. 2003. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int, 63:12-23.
3. Bonetti PO, Wilson SH, Rodriguez-Porcel M, et al. 2002. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol, 40:546-54.
4. Bourcier T, Libby P. 2000. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol, 20:556-62.
5. Bustos C, Hernández-Presa MA, Ortego M, et al. 1998. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 32:2057-64.
6. Ceriello A, Assaloni R, Da Ros R, et al. 2005. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation, 111:2518-24.
7. Chen J, Li D, Schaefer R, et al. 2006. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis, 184:295-301.
8. Cipollone F, Fazia M, Iezzi A, et al. 2004. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation, 109:1482-8.
9. Corriu C, Bernard S, Schott C, et al. 1995. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol, 26:688-92.
10. Crabos M, Brertschin S, Bühler FR, et al. 1993. Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens Suppl, 11:S230-1.
11. Dahlof B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366:895-906.
12. Dandona P, Kumar V, Aljada A, et al. 2003. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab, 88:4496-501.
13. Davi G, Averna M, Catalano I, et al. 1992. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation, 85:1792-8.
14. Diet F, Pratt RE, Berry G J, et al. 1996. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation, 94:2756-67.
15. Essig M, Nguyen G, Prie D, et al. 1998. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res, 83:683-90.
16. Eto M, Kozai T, Cosentino F, et al. 2002. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 105:1756-9.
17. Fliser D, Buchholz K, Haller H, et al. 2004. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation, 110:1103-7.
18. Glorioso N, Troffa C, Filigheddu F, et al. 1999. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension, 34:1281-6.
19. Grandaliano G, Biswas P, Choudhury GG, et al. 1993. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int, 44:503-8.
20. Harrison DG, Venema RC, Arnal JF, et al. 1995. The endothelial cell nitric oxide synthase: is it really constitutively expressed? Agents Actions Suppl, 45:107-17.
21. He M, He X, Xie Q, et al. 2006. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res, 117:579-90.
22. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
23. Hernández-Presa M, Bustos C, Ortego M, et al. 1997. Angiotensin Converting enzyme inhibition prevents arterial NF-kB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation, 95:1532-41.
24. Hernández-Presa MA, Bustos C, Ortego M, et al. 1998. The ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflammatory factors but not of collagen in a rabbit model of atherosclerosis. Am J Pathol, 153:1825-37.
25. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. 2002. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis, 160:49-58.
26. Ischiropoulos H, Al-Mehdi AB. 1995. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett, 364:279-82.
27. Ito K, Ikeda U, Yamamoto K, et al. 2002. Regulation of interieukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis, 165:51-5.
28. Ito A, Tsao PS, Adimoolam S, et al. 1999. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation, 99:3092-5.
29. Iwanciw D, Rehm M, Porst M, et al. 2003. Induction of connective tissue growth factor by angiotensin II: integration of signaling pathways. Arterioscler Thromb Vasc Biol, 23:1782-7.
30. James IM, Dickenson EJ, Burgoyne W, et al. 1988. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens, 2:21-5.
31. Kannel WB, Dawber TR, Kagan A, et al. 1961. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med, 55:33-50.
32. Keidar S, Attias J. 1997. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun, 239:63-7.
33. Kim SI, Han DC, Lee HB. 2000. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol, 11:80-7.
34. Koh KK, Chung WJ, Ahn JY, et al. 2004. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis, 177:155-60.
35. Laufs U, La Fata V, Plutzky J, et al. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97:1129-35.
36. Luan Z, Chase AJ, Newby AC. 2003. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol, 23:769-75.
37. Luchtefeld M, Grote K, Grothusen C, et al. 2005. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun, 328:183-8.
38. Mancini GB, Henry GC, Macaya C, et al. 1996. Angiotensin-converting enzyme inhibition with qninapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation, 94:258-65. Erratum in: Circulation, 1996;94:1490.
39. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, et al. 2005. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke, 36:1796-800.
40. McGill HG. 1996. Major risk factors and primary prevention: Overview. In: Fuster V, Ross R, Topol E (eds). Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, p 25-41.
41. Morawietz H, Rueckschloss U, Niemann B, et al. 1999. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation, 100:899-902.
42. Nickenig G, Bäumer AT, Temur Y, et al. 1999. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation, 100:2131-4.
43. Nickenig G, Sachinidis A, Michaelsen F, et al. 1997. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation, 95:473-8.
44. Notarbartolo A, Davi G, Averna M, et al. 1995. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol, 15:247-51.
45. O'Driscoll G, Green D, Taylor RR. 1997. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95:1126-31.
46. Ortego M, Bustos B, Hernández-Presa MA, et al. 1999. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 147:253-6.
47. Ortego M, Gómez Hernández A, Vidal C, et al. 2005. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol, 45:468-75.
48. Poulter NR, Wedel H, Dahlof B, et al. 2005. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Ann (ASCOT-BPLA), Lancet, 366:907-13.
49. Rajagopalan S, Kurz S, Münzel T, et al. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidasc activation. Contribution to alterations to vasomotor tone. J Clin Invest, 97:1916-23.
50. Ray KK, Cannon CP. 2005. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol, 46:1425-33.
51. Riaz AA, Wang Y, Schramm R et al. 2004. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J, 18:881-3.
52. Robbesyn F, Garcia V, Auge N, et al. 2003. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J, 17:743-5.
53. Rupérez M, Lorenzo O, Blanco-Colio LM, et al. 2003. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation, 108:1499-505.
54. Schieffer B, Bunte C, Witte J, et al. 2004. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol, 44:362-8.
55. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. 2000. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation, 101:1372-8.
56. Sever PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Ann (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361:1149-58.
57. Toschi V, Gallo R, Lettino M, et al. 1997. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation, 95:594-9.
58. Tuñón J, Barderas MG, Jiménez-Nácher JJ, et al. 2007. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. J Am Coll Cardiol, 49(Suppl A):355A.
59. Tuñón J, Egido J. 2004. Endothelial dysfunction, inflammation and statins: new evidences. Rev Esp Cardiol, 57:903-5.
60. Ushio-Fukai M, Alexander RW, Akers M, et al. 1998. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem, 273:15022-9.
61. Vaughan DE, Rouleau JL, Pfeffer MA. 1995. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J, 16(Suppl K):31-6.
62. Victorino GP, Newton CR, Curran B. 2002. Effect of angiotensin II on microvascular permeability. J Surg Res, 104:77-81.
63. Warnholtz A, Nickenig G, Schulz E, et al. 1999. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation, 99:2027-33.
64. Wong J, Rauhoft C, Dilley RJ, et al. 1997. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation, 96:1631-40.
65. Wright RA, Flapan AD, Alberti KG, et al. 1994. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol, 24:67-73.
66. Xu XP, Meisel SR, Ong JM, et al. 1999. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation, 99:993-8.
67. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.